N/A N=80 Randomized Double-blind Treatment

Transversus Abdominis Plane Block Versus Wound Infiltration for Postcesarean Analgesia

Postcesarean Analgesia

Bottom Line

View on ClinicalTrials.gov: NCT02691572 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2018

Primary outcome: Primary: Cumulative Fentanyl Dose — 157.4; 153.3 mcg

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Spinal anesthesia (Procedure); Intrathecal bupivacaine (Drug); Intrathecal fentanyl (Drug); Cesarean delivery (Procedure); Wound infiltration (Procedure); Sham procedure (Procedure); Transversus abdominis plane block (Procedure); Ketorolac (Drug); Paracetamol (Drug); Fentanyl patient-controlled analgesia (Procedure)
Age: Adult · 19+ yrs
Sex: Female
Sponsor: Mansoura University
Primary completion: May 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Cumulative Fentanyl Dose	—	—
SECONDARY Cumulative Fentanyl Dose	—	—
SECONDARY Time to the First Postoperative Fentanyl Administration	—	—
SECONDARY Pain Scores at Rest and Movement	—	—
SECONDARY Number of Patients With Nausea and/or Vomiting	—	—
SECONDARY Level of Sedation	—	—
SECONDARY Number of Patients With Pruritis	—	—
SECONDARY Level of Patient Satisfaction	—	—

Summary

The study will compare the analgesic efficacy of transversus abdominis plane block and wound infiltration in parturients undergoing cesarean delivery under spinal anesthesia.

Eligibility Criteria

Inclusion Criteria

American Society of Anesthesiologists physical status II
Full-term singleton pregnancy

Exclusion Criteria

Age 40 years
Height <150 cm
Weight <60 kg
Body mass index ≥40 kg/m2
Contraindications to spinal anesthesia (patient refusal, increased intracranial tension, coagulopathy, uncorrected hypovolemia)
Hypersensitivity to any of the drugs used in the study
Significant cardiovascular, renal, or hepatic disease
Known fetal abnormalities
Emergency situations

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02691572). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.